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ABSTRACT
Posterior reversible encephalopathy syndrome (PRES) is a rare syndrome that presents with neurological manifestations, often associated 
with arterial hypertension. Magnetic resonance imaging (MRI) shows bilateral white matter oedema in the posterior vascular territories. 
Immunosuppression, (pre) eclampsia and autoimmune diseases can be implicated. A 27-year-old woman, with mixed connective tissue 
disease under azathioprine, was admitted in the emergency room in status epilepticus and with severe hypertension. The MRI showed 
bilateral oedema in a pattern compatible with PRES. There was clinical improvement after azathioprine suspension. PRES is typically 
reversible with prompt recognition of the syndrome and its trigger. The association with azathioprine is rare. 
LEARNING POINTS
• Posterior reversible encephalopathy syndrome should be considered in patients with sudden onset of headache, altered consciousness 
and seizures.
•	 Recognition	of	this	entity	and	identification	of	the	trigger	are	essential	for	reversal	of	the	clinical	picture.
•	 Autoimmune	 diseases	 and	 some	 immunosuppressive	 drugs	 have	 been	 identified	 as	 causative,	 but	 reports	 of	 an	 association	 with	
azathioprine are very rare.
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CASE DESCRIPTION
We present the case of a 27-year-old woman with a history of mixed connective tissue disease, medicated with azathioprine 125 mg/day, 
with controlled disease. Within 1 month of azathioprine initiation, she complained of headache and palinopsia of 1 weeks’ duration. After a 
generalized tonic–clonic seizure, she was admitted to the emergency department in status epilepticus, presenting with high blood pressure 
(200/100	mm	Hg),	but	without	focal	neurological	signs.	The	laboratory	findings	were	otherwise	normal,	with	no	inflammatory	parameters	
or other relevant changes. The lumbar puncture was not suggestive of central nervous system infection.
Magnetic resonance imaging (MRI) showed bilateral vasogenic oedema in the frontal, temporal, parietal and occipital cortico-subcortical 
regions compatible with reversible posterior encephalopathy (PRES) (Fig. 1) and a left occipital haemorrhagic lesion (Fig. 2). 
The arterial study did not reveal any changes in the circle of Willis or neck vessels. Due to the refractory status epilepticus, the patient was 
intubated and ventilated. Azathioprine was suspended and, based on the suspicion that the autoimmune disease was the trigger, pulses of 
methylprednisolone were administered. The patient remained sedated for 48 hours, followed by neurological recovery and progressive 
regression of the MRI lesions.
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Figure 1. Hyperintense bilateral 
heterogeneous T2 sign involving the 
frontal, temporal, occipital and parietal 
cortico-subcortical regions (diffusion-
weighted), suggestive of vasogenic oedema 
and compatible with reverse posterior 
encephalopathy
With clinical improvement, after multidisciplinary discussion, it was decided to cease anticonvulsant therapy, resume previous medication 
with azathioprine and initiate steroid tapering. The patient was discharged after 26 days of hospitalization with no symptoms.
However, 1 week after reintroduction of azathioprine at the previous dose, there was recurrence of the fronto-temporal headache, which 
was intense and pulsatile, and similar to that described before the diagnosis of PRES. A new MRI was performed and the result was similar 
to	the	previous	findings:	there	was	no	clinical	or	analytical	evidence	of	an	autoimmune	flare.	Given	the	similarity	of	the	complaints,	it	was	
assumed that the cause of PRES was azathioprine. There was complete resolution of the clinical picture with discontinuation of the drug.
DISCUSSION
PRES	 is	 a	 rare	and	possibly	underdiagnosed	 syndrome,	with	no	 specific	well-defined	diagnostic	 criteria.	Due	 to	 the	 lack	of	 randomized	
studies, actual knowledge of this condition comes from case reports and retrospective studies[1]. 
PRES	 is	 characterized	 by	 several	 neurological	 signs	 and	 symptoms	 associated	with	 typical	 imaging	 findings,	 corresponding	 to	 areas	 of	
vasogenic cerebral oedema[1].	 It	 is	 defined	as	 a	 clinical-radiological	 entity,	with	acute/sub-acute	onset	of	headache,	 visual	disturbances,	
nausea/vomiting, altered mental status, seizures and focal signs, usually associated with arterial hypertension[1,2].
Neuroimaging,	 in	 particular	 magnetic	 resonance	 findings,	 most	 often	 shows	 bilateral	 white	 matter	 oedema	 in	 the	 posterior	 vascular	
territories (parietal and occipital lobes)[2–4]. 
Figure 2. Left occipital haemorrhagic lesion
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Its pathophysiology is still not fully understood, but an association with pre-eclampsia/eclampsia, immunosuppression and autoimmune 
diseases is documented[1,3]. PRES is typically a reversible condition if there is prompt recognition of the syndrome and its triggering 
factor. Treatment is mainly supportive and symptomatic, but it is essential to eliminate the precipitating cause and control elevated blood 
pressure[3,5]. Anticonvulsant therapy is recommended in patients with seizures, and can be discontinued when patients are asymptomatic 
and imaging abnormalities have resolved[1].
The association with autoimmune diseases and immunosuppressive therapy has been described, although the responsible mechanism 
is not fully understood. Reports have implicated different drugs, but the association with azathioprine is extremely rare [6]. In our case, 
the recurrence following reintroduction of the drug and clinical improvement with complete reversal of the clinical status following drug 
suspension/discontinuation is strongly suggestive of this association. 
